Logo image of TBP.CA

Tetra Bio Pharma Inc (TBP.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:TBP - CA88166Y1007 - Common Stock

0.025 CAD
0 (0%)
Last: 3/6/2023, 7:00:00 PM
Fundamental Rating

0

Taking everything into account, TBP scores 0 out of 10 in our fundamental rating. TBP was compared to 30 industry peers in the Pharmaceuticals industry. TBP may be in some trouble as it scores bad on both profitability and health. TBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TBP has reported negative net income.
TBP had a negative operating cash flow in the past year.
TBP.CA Yearly Net Income VS EBIT VS OCF VS FCFTBP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for TBP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBP.CA Yearly ROA, ROE, ROICTBP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -5K -10K -15K -20K

1.3 Margins

TBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBP.CA Yearly Profit, Operating, Gross MarginsTBP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, TBP has more shares outstanding
Compared to 1 year ago, TBP has a worse debt to assets ratio.
TBP.CA Yearly Shares OutstandingTBP.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M
TBP.CA Yearly Total Debt VS Total AssetsTBP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -70.85, we must say that TBP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -70.85, TBP is doing worse than 92.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.85
ROIC/WACCN/A
WACCN/A
TBP.CA Yearly LT Debt VS Equity VS FCFTBP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M -10M 20M -20M

2.3 Liquidity

TBP has a Current Ratio of 0.25. This is a bad value and indicates that TBP is not financially healthy enough and could expect problems in meeting its short term obligations.
TBP has a worse Current ratio (0.25) than 88.24% of its industry peers.
A Quick Ratio of 0.25 indicates that TBP may have some problems paying its short term obligations.
TBP has a worse Quick ratio (0.25) than 84.31% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
TBP.CA Yearly Current Assets VS Current LiabilitesTBP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.30% over the past year.
EPS 1Y (TTM)7.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBP.CA Price Earnings VS Forward Price EarningsTBP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBP.CA Per share dataTBP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.02 -0.04 -0.06 -0.08

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Tetra Bio Pharma Inc

TSX:TBP (3/6/2023, 7:00:00 PM)

0.025

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners3.35%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.58M
Revenue(TTM)N/A
Net Income(TTM)-39.02M
Analysts84
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.24%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -70.85
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3021.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.7%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.63%
OCF growth 3YN/A
OCF growth 5YN/A

Tetra Bio Pharma Inc / TBP.CA FAQ

What is the fundamental rating for TBP stock?

ChartMill assigns a fundamental rating of 1 / 10 to TBP.CA.


Can you provide the valuation status for Tetra Bio Pharma Inc?

ChartMill assigns a valuation rating of 0 / 10 to Tetra Bio Pharma Inc (TBP.CA). This can be considered as Overvalued.


Can you provide the profitability details for Tetra Bio Pharma Inc?

Tetra Bio Pharma Inc (TBP.CA) has a profitability rating of 1 / 10.